Document: DOCUMENT 4: IMMUNOSUPPRESSIVE DRUGS - MECHANISM OF ACTION AND PHARMACOLOGY
Chunks: 18
Organ: foundational
================================================================================

[Doc_4_Immunosuppressive_Drugs:chunk_000] 1. OVERVIEW: TARGETS IN THE IMMUNE RESPONSE
Tokens: 123
--------------------------------------------------------------------------------
The immune response to transplanted organ proceeds through distinct stages, each presenting therapeutic targets[1]:

| Stage | Target Cells/Molecules | Drugs | Mechanism |
|-------|----------------------|-------|-----------|
| Antigen Presentation | Dendritic cells, APC | Corticosteroids, CNI, Monoclonal Abs | Block costimulation, IL-2 production |
| T-Cell Priming | T-cell receptor, Costimulation (CD28) | CNI, Belatacept, Monoclonal Abs | Block TCR signaling, CD28-B7 interaction |
| T-Cell Proliferation | IL-2R signaling, DNA synthesis | Antimetabolites (MPA, AZA), mTOR inhibitors | Reduce nucleotide synthesis; block mTOR |
| B-Cell Response | B-cell activation, Germinal centers | Rituximab, other monoclonal Abs | Deplete B cells, plasma cells |
| Effector Function | T-cell trafficking, cytokine production | Corticosteroids, CNI | Reduce cytokine production, cell migration |

---

[Doc_4_Immunosuppressive_Drugs:chunk_001] 2.1 Mechanism of Action
Tokens: 129
--------------------------------------------------------------------------------
Calcineurin enzyme:
Calcineurin (also called protein phosphatase 2B) is a serine-threonine phosphatase that plays a critical role in T-cell activation[1]:

1. When T-cell receptor (TCR) engages antigen-HLA complex and CD28 receives costimulation, calcium enters the T cell
2. Increased intracellular Ca²⁺ activates calcineurin
3. Calcineurin dephosphorylates NFAT (nuclear factor of activated T cells)
4. Dephosphorylated NFAT translocates to nucleus
5. NFAT binds to IL-2 promoter region
6. IL-2 gene transcription occurs
7. IL-2 protein produced; binds IL-2 receptor on T cells → T-cell proliferation

CNI action:
Tacrolimus binds FK-binding protein (FKBP12), forming a complex that inhibits calcineurin
Cyclosporine binds cyclophilin, forming a complex that inhibits calcineurin
Both complexes are highly specific, potent calcineurin inhibitors
Block IL-2 and other pro-inflammatory cytokine (TNF-α, IFN-γ, IL-4, IL-5) production
T-cell proliferation suppressed dramatically

[Doc_4_Immunosuppressive_Drugs:chunk_002] 2.2 Tacrolimus (Prograf, FK506)
Tokens: 361
--------------------------------------------------------------------------------
Chemical properties:
Macrolide antibiotic analog
Highly lipophilic
Molecular weight 822 Da

Pharmacokinetics:

| Parameter | Value |
|-----------|-------|
| Bioavailability (PO) | 7-20% (wide variability; fasting vs. fed state markedly affects) |
| Protein binding | 98-99% (primarily albumin, α1-acid glycoprotein) |
| Tmax | 1-3 hours (varies with formulation) |
| Distribution | Large volume of distribution; tissue accumulation |
| Metabolism | CYP3A4/3A5 (primarily; minor CYP2D6) |
| Elimination | Hepatic metabolism; <1% renal excretion of unchanged drug |
| Half-life | 12-15 hours (wide range 8-24 hours; influenced by GFR, liver function) |
| Therapeutic level | 5-15 ng/mL (varies by assay, time post-transplant, organ type) |

Formulations:
Immediate-release (BID dosing): Traditional formulation; requires BID dosing; unpredictable absorption
Extended-release (Advagraf, Astagraf XL): Once-daily formulation; more consistent trough levels; convenient
IV formulation: For patients unable to take PO (perioperative, ICU); rapid infusion (>1 hour) to avoid cardiotoxicity

Advantages over cyclosporine:
More potent (lower doses needed)
Better oral bioavailability (though still variable)
Faster onset of action
Lower incidence of gingival hyperplasia, hirsutism
Less hypertension
Fewer drug interactions (though still significant)
Lower cardiovascular event risk

Disadvantages:
Nephrotoxicity (major concern; dose-limiting toxicity)
Neurotoxicity (tremor, headache, encephalopathy at high levels)
Hyperglycemia (dose-dependent; post-transplant diabetes mellitus risk)
Hypertension
Hyperlipidemia
Gingival hyperplasia (less common than cyclosporine, but occurs)
Alopecia
Variable PO absorption (especially early post-transplant with diarrhea, vomiting)
Interactions with CYP3A4/3A5 substrates

Drug interactions (CYP3A4/3A5 inducers/inhibitors):

| Effect | Drugs | Action |
|--------|-------|--------|
| Increase tacrolimus levels | Diltiazem, verapamil (calcium channel blockers); azole antifungals (fluconazole, itraconazole); macrolide antibiotics (erythromycin, azithromycin); protease inhibitors | Inhibit CYP3A4 → reduce tacrolimus metabolism |
| Decrease tacrolimus levels | Rifampin, rifabutin; phenytoin; carbamazepine; St. John's Wort | Induce CYP3A4 → increase tacrolimus metabolism |
| Mutual interaction | Other CNI substrates | Variable levels; monitoring essential |

Monitoring:
Therapeutic drug monitoring (TDM): Trough level measurement (just before next dose) using HPLC or LC-MS/MS
Timing: Pre-dose trough most reproducible
Target levels vary by:
Time post-transplant (higher initially; lower at months 3-6+)
Organ type (kidney, liver, heart, lung have different targets)
Presence of HLA mismatch/acute rejection (higher targets)
Baseline renal function (may require lower levels if CNI-related toxicity)

---

[Doc_4_Immunosuppressive_Drugs:chunk_003] 2.3 Cyclosporine (Sandimmune, Neoral)
Tokens: 258
--------------------------------------------------------------------------------
Chemical properties:
Cyclic undecapeptide (11 amino acids)
Hydrophobic; lipophilic
Molecular weight 1203 Da

Pharmacokinetics:

| Parameter | Value |
|-----------|-------|
| Bioavailability (PO) | 20-50% (Neoral formulation improved over Sandimmune) |
| Protein binding | 90-98% (primarily lipoproteins; temperature-dependent) |
| Tmax | 2-6 hours |
| Distribution | High tissue accumulation |
| Metabolism | CYP3A4 (primarily); also CYP2D6, 2C19 |
| Elimination | Hepatic; biliary excretion; <1% renal |
| Half-life | 10-27 hours (highly variable) |
| Therapeutic level | 100-300 ng/mL (variable; depends on assay, time post-transplant) |

Formulations:
Sandimmune: Original formulation; poor, unpredictable absorption
Neoral (microemulsion): Improved formulation; better absorption, less dependent on bile
IV formulation: For perioperative use; slower infusion to minimize cardiotoxicity

Advantages:
Decades of use; extensive clinical experience
Potential hepatoprotective effects (liver transplant)
Lower incidence of post-transplant diabetes (vs. tacrolimus)

Disadvantages (Many!): Lower potency: Higher doses needed than tacrolimus
Poor oral bioavailability: Highly variable, unpredictable; affected by:
Food intake (especially fatty foods)
Bile flow (cholestasis increases levels)
GI motility disorders
Diarrhea reduces absorption
Nephrotoxicity: Similar to tacrolimus; dose-limiting
Hypertension: Very common; 50-80% of recipients
Hyperlipidemia: More common than with tacrolimus
Gingival hyperplasia: Very common (20-50%); unsightly; may require gingivectomy
Hirsutism/hypertrichosis: Common; cosmetically problematic
Hepatotoxicity: At high doses
Neurotoxicity: Similar to tacrolimus
Multiple drug interactions: CYP3A4 inhibitors/inducers markedly affect levels
Difficult monitoring: Highly variable PK; requires frequent TDM adjustments
Cost: More expensive than tacrolimus

Drug interactions: Similar to tacrolimus (CYP3A4-mediated)

Monitoring:
TDM using HPLC or LC-MS/MS
Requires more frequent monitoring due to unpredictability
Target levels higher than tacrolimus for similar immunosuppression

[Doc_4_Immunosuppressive_Drugs:chunk_004] 2.4 CNI-Related Adverse Effects
Tokens: 408
--------------------------------------------------------------------------------
#### Nephrotoxicity (Chronic CNI Toxicity)

Mechanisms:
1. Vasoconstriction: CNI reduce nitric oxide (NO) and increase vasoconstrictive mediators (endothelin, renin-angiotensin system activation) → afferent arteriole vasoconstriction → ↓ GFR
2. Direct tubular toxicity: Mitochondrial dysfunction, oxidative stress, apoptosis of tubular cells
3. Interstitial fibrosis: Fibroblast activation, TGF-β signaling → collagen deposition
4. Glomerular injury: Hyaline arteriolosis; glomerulosclerosis
5. Arteriolar sclerosis: Hyaline thickening of arterioles in afferent vessels

Clinical presentation:
Gradual rise in serum creatinine over weeks to months
Loss of GFR 5-10 mL/min per year (vs. 1-2 mL/min/year without CNI toxicity)
Electrolyte abnormalities: hyperkalemia (from decreased renal perfusion, reduced aldosterone), hypomagnesemia
Oliguria may develop if severe

Risk factors:
High CNI trough levels (>15 ng/mL for tacrolimus)
Prolonged high-level exposure (years)
Older age
Pre-existing renal insufficiency
Dehydration
NSAIDs (worsen renal hemodynamics)
ACE-I/ARB use (can improve, but initial rise in creatinine expected)

Prevention:
Target CNI levels appropriately: Lower levels as time post-transplant increases
Minimize CNI exposure: Consider CNI-sparing regimens (belatacept, mTOR inhibitor-based)
Monitor renal function closely: Serial creatinine, GFR
Avoid concurrent nephrotoxins: NSAIDs, radiocontrast (minimize), aminoglycosides
Optimize renal perfusion: Maintain euvolemia; avoid dehydration
ACE-I/ARB: Provide renal protection; use if tolerated (transient Cr increase expected)

Management:
Reduce CNI dose; target lower trough levels (risk: rejection)
Switch to alternative agent (belatacept, mTOR inhibitor; less data on reversal of established toxicity)
Aggressive management of hypertension, proteinuria
Monitor for progression to end-stage renal disease

#### Hyperglycemia and Post-Transplant Diabetes Mellitus (PTDM)

Incidence: 
Tacrolimus: 15-25% new-onset PTDM (vs. 5-10% with cyclosporine)
Risk factors: Tacrolimus use, African American race, older age, obesity, family history of diabetes

Mechanisms:
β-cell dysfunction: CNI inhibit calcineurin in pancreatic β cells → reduced insulin secretion in response to glucose
Insulin resistance: CNI may impair insulin signaling (PI3K pathway)
Genetic predisposition: Increased incidence in those with genetic susceptibility to type 2 diabetes

Management:
Prevention: Minimize CNI doses; screen for risk factors
Monitoring: Fasting glucose, HbA1c at baseline, 3-6 months, annually
Treatment: Lifestyle modification (diet, exercise); oral agents (metformin preferred); insulin if severe
Note: Once diagnosed, difficult to reverse even with CNI minimization

#### Hypertension

Incidence: 50-80% of transplant recipients on CNI

Mechanisms:
Renal vasoconstriction → activation of renin-angiotensin system
Sympathetic nervous system activation
Reduced NO production → loss of vasodilation
Increased endothelin production
Sodium retention

Management:
First-line: ACE-I or ARB (block RAAS; provide renal protection; reduce proteinuria)
Second-line: Calcium channel blockers (diltiazem, verapamil; also inhibit CYP3A4 → increase CNI levels—double benefit)
Third-line: Beta-blockers, diuretics as needed
Target: <130/80 mmHg (cardiovascular risk reduction)

---

[Doc_4_Immunosuppressive_Drugs:chunk_005] 3.2 Mycophenolate Mofetil (MMF)
Tokens: 259
--------------------------------------------------------------------------------
Pharmaceutical form:
Pro-drug: rapidly metabolized to active MPA
Formulation: Gelatin capsules or tablets
Dosing: 500-1500 mg BID (1-3 g daily)

Pharmacokinetics:

| Parameter | Value |
|-----------|-------|
| Route | Oral |
| Protein binding | 97% (albumin) |
| Metabolism | Rapid ester hydrolysis → MPA → glucuronidation → MPAG (inactive metabolite) |
| MPAG enterohepatic recirculation | 40-50%; may increase bioavailability with higher MPA exposure |
| Tmax | 0.5-2 hours |
| Half-life (MPA) | 16-18 hours |
| Bioavailability | 94% (rapid absorption) |
| Renal elimination | 87% renal (MPAG); renal impairment may increase MPAG levels |

Advantages:
Potent lymphocyte suppression
GI absorption rapid; predictable levels
Relatively safe toxicity profile
Can be used in combination with CNI and corticosteroids
Doses can be escalated as needed
Better outcomes vs. AZA in some studies

Disadvantages:
GI toxicity: Most common side effect
Dose-dependent diarrhea (15-30% at higher doses)
Nausea, vomiting (20-30%)
Dyspepsia
Abdominal cramps
Neutropenia: Can develop; requires monitoring
Infection risk: Similar to other immunosuppressants
Reproductive toxicity: Highly teratogenic (Category X); absolute contraindication in pregnancy
Cost: Expensive (though generic available)

Monitoring:
Complete blood count: Monitor for neutropenia
No established TDM (unlike CNI); dosing based on clinical response and toxicity
Emerging: Some centers use MPA level monitoring (IMPDH activity or AUC measurement); limited clinical utility
Liver function tests (baseline)

Interactions:
Antacids: Reduce MPA absorption; separate dosing by ≥2 hours
Iron supplements: Reduce MPA absorption; separate dosing
Acyclovir/valacyclovir: Competition for renal tubular secretion; may increase both drug levels
Azathioprine/AZA: Avoid concurrent use (both target same pathway; no additive benefit)

[Doc_4_Immunosuppressive_Drugs:chunk_006] 3.3 Enteric-Coated Mycophenolate (EC-MPA, Myfortic)
Tokens: 116
--------------------------------------------------------------------------------
Pharmaceutical form:
Enteric-coated tablet; delayed-release formulation
Designed to release in small intestine (pH-dependent)
Dosing: 360-720 mg BID (equivalent to 1-1.5 g MMF BID)

Rationale for development:
Reduce GI side effects (MPA concentration in colon believed responsible for diarrhea)
Maintain efficacy

Pharmacokinetics:
Delayed tmax (2-3 hours vs. 0.5-2 hours for MMF)
Peak levels lower; more prolonged absorption
AUC comparable to MMF (similar total drug exposure)
Bioavailability ~70% of MMF (hence higher dosing for equivalence)

Advantages over MMF:
Reduced GI toxicity: Less diarrhea, nausea in some studies (not all)
Convenient dosing: BID (vs. QID)
Less drug interaction with antacids (though should still separate dosing)

Disadvantages:
More expensive than MMF
May have slightly lower peak levels
Similar teratogenicity

---

[Doc_4_Immunosuppressive_Drugs:chunk_007] 3.4 Azathioprine (Imuran, AZA)
Tokens: 182
--------------------------------------------------------------------------------
Mechanism:
Pro-drug metabolized to 6-mercaptopurine (6-MP)
6-MP converted to thioinosinate → inhibits IMPDH and other enzymes in purine synthesis
Less selective than MPA; affects other cell types more

Pharmacokinetics:
Rapid, complete absorption
Metabolized by xanthine oxidase and thiopurine methyltransferase (TPMT)
Half-life 0.5-3 hours

Advantages:
Lower cost: Much cheaper than MPA
Long history: Extensive experience; safe in pregnancy (relative advantage for teratogenicity vs. MMF)
Oral absorption: Can use if MMF not tolerated
Dual pathway inhibition: May be slightly different from MPA

Disadvantages:
Less potent: Generally inferior outcomes vs. MPA
GI toxicity: Similar to MMF (diarrhea, nausea)
Bone marrow suppression: More common than MPA
Neutropenia (dose-dependent; reversible)
Anemia
Thrombocytopenia
TPMT polymorphism: Genetic variation in TPMT (slow metabolizers at risk for toxicity)
Consider TPMT testing before initiation; dose reduce if deficient
Drug interactions:
Allopurinol: Inhibits xanthine oxidase → increases AZA levels; reduce AZA dose by 66-75%
ACE-I/ARB: May increase bone marrow suppression (avoid if possible)
Trimethoprim-sulfamethoxazole (TMP-SMX): Increased bone marrow toxicity
Hepatotoxicity: Monitor LFTs
Infection risk: Similar to other agents

Monitoring:
CBC: Monitor for cytopenia
LFTs: Baseline and periodic
TPMT testing: Consider before initiation

---

[Doc_4_Immunosuppressive_Drugs:chunk_008] 4.3 Adverse Effects (Extensive)
Tokens: 167
--------------------------------------------------------------------------------
Corticosteroids have a vast array of side effects, particularly with prolonged use:

| System | Adverse Effect | Frequency | Management |
|--------|---|---|---|
| Endocrine | Hyperglycemia, PTDM | Very common | Insulin, oral agents |
| Metabolic | Dyslipidemia, hypertriglyceridemia | Very common | Statins, dietary modification |
| Musculoskeletal | Osteoporosis, avascular necrosis | Common | Calcium, vitamin D, bisphosphonates |
| Infectious | Increased infections | Very common | Appropriate prophylaxis, monitoring |
| GI | Peptic ulcer disease, GI bleeding | Infrequent (low-dose) | PPI, avoid NSAIDs |
| Psychiatric | Mood changes, psychosis | Rare-infrequent | Monitor; taper if severe |
| Ophthalmologic | Cataracts, glaucoma | Infrequent | Annual eye exam |
| Dermatologic | Easy bruising, striae, acne | Common | Cosmetic management |
| Cardiovascular | Hypertension, fluid retention | Very common | Diuretics, ACE-I/ARB |
| Neurologic | Tremor, headache | Infrequent | Monitor; adjust dose |
| Hepatic | Mild transaminitis | Infrequent | Monitor LFTs |

[Doc_4_Immunosuppressive_Drugs:chunk_009] 4.4 Steroid Minimization and Withdrawal
Tokens: 132
--------------------------------------------------------------------------------
Rationale:
Reduce adverse effects
Improve quality of life
Reduce PTDM incidence
Reduce cardiovascular events

Approaches:

1. Steroid minimization: Taper to lowest effective dose (2.5-7.5 mg daily)
Requires adequate other immunosuppression (CNI, antimetabolites)
Monitor for rejection (higher risk)
Most commonly used strategy

2. Steroid-free protocols: Complete withdrawal within weeks of transplant
Suitable for low-risk recipients (first transplant, low immunologic risk, excellent adherence)
Requires induction therapy (lymphocyte-depleting agent)
5-10% acute rejection risk (vs. 2-5% on maintenance steroids)
Long-term outcomes mixed (some improved, some worse)
Not recommended in:
High HLA mismatch
Pre-existing DSA
High immunologic risk
African American race (higher rejection risk)

Steroid withdrawal protocols:
Gradual taper over weeks to months (avoids adrenal insufficiency)
Support with stress-dose steroids (e.g., 50 mg prednisone × 3 days) if major stressor (infection, surgery)
Monitoring for rejection indicators

---

[Doc_4_Immunosuppressive_Drugs:chunk_010] 5.2 Sirolimus (Rapamune)
Tokens: 237
--------------------------------------------------------------------------------
Pharmacokinetics:
Highly lipophilic; large molecular weight (914 Da)
Protein binding: 92%
Metabolized by CYP3A4; ~90% biliary elimination
Half-life: 57-63 hours (very long; requires loading dose or several weeks to reach steady state)
Tmax: 1-3 hours

Dosing:
Loading dose: Typically 6 mg (though some skip if rapid initiation not needed)
Maintenance: 2-5 mg daily (target trough 5-10 ng/mL early post-transplant; 3-5 ng/mL later)

Advantages:
Potent immunosuppression
Anti-proliferative effects on SMC; may reduce vasculopathy risk
Anti-fibrotic properties; may reduce IFTA
No CNI-related nephrotoxicity
Can be used with low-dose or no CNI (CNI-sparing)
No significant drug metabolism interaction (though substrate of CYP3A4)

Disadvantages:
Delayed wound healing: Major concern perioperative
Impaired renal function recovery: Problematic early post-transplant (especially kidney transplant with DGF)
Dyslipidemia: Elevation of cholesterol, triglycerides
Thrombocytopenia/anemia: Bone marrow effects; monitor CBC
GI toxicity: Diarrhea, nausea, stomatitis
Proteinuria: May increase existing proteinuria
Pneumonitis: Rare but serious; increased risk especially early post-transplant
Lymphocele: Increased risk post-operatively (impaired lymphatic healing)
Complex drug interactions: CYP3A4 substrate; affected by CNI
Long half-life: Requires weeks to eliminate if discontinued
Monitoring burden: Requires frequent TDM

Monitoring:
Trough levels: HPLC or LC-MS/MS
CBC: Monitor for cytopenias
Lipid panel: Baseline, 1 month, 3 months, then periodically
LFTs: Baseline and periodically
Proteinuria: Baseline and periodic

Drug interactions:
Strong CYP3A4 substrate; significantly affected by inhibitors/inducers
Increased levels: CNI (tacrolimus, cyclosporine), azole antifungals, diltiazem, verapamil
Decreased levels: Rifampin, carbamazepine, phenytoin
Mutual levels: With CNI; often requires dose reduction of both

---

[Doc_4_Immunosuppressive_Drugs:chunk_011] 5.3 Everolimus (Certican, Afinitor)
Tokens: 130
--------------------------------------------------------------------------------
Comparison to sirolimus:
Structural analog of sirolimus
Similar mechanism (mTORC1 inhibition via FKBP12 complex)
Shorter half-life (~30 hours vs. 57 hours for sirolimus)
Faster achievement of steady state

Pharmacokinetics:
Half-life: 28-35 hours
Protein binding: 74%
Metabolism: CYP3A4; biliary/fecal elimination
Tmax: 1-2 hours

Dosing:
Starting dose: 0.75 mg BID
Target trough: 3-8 ng/mL
Typical maintenance: 1-2 mg BID

Advantages over sirolimus:
Shorter half-life: Faster elimination if discontinued (useful if toxicity)
BID dosing: Better compliance in some; worse in others
Faster steady state: Can adjust quickly
Potentially fewer drug interactions (though still CYP3A4 substrate)

Disadvantages:
Similar to sirolimus
Requires BID dosing (vs. daily for sirolimus)
More frequent TDM monitoring

Use in transplantation:
Less commonly used than sirolimus in US
More commonly used in Europe
Often combined with reduced-dose CNI ("CNI-sparing" regimens)

---

[Doc_4_Immunosuppressive_Drugs:chunk_012] 6.1 Mechanism of Action
Tokens: 112
--------------------------------------------------------------------------------
T-cell activation requires two signals:

1. Signal 1 (TCR engagement): T-cell receptor recognizes antigen-HLA complex on APC
2. Signal 2 (costimulation): CD28 on T cell binds to B7 molecules (CD80, CD86) on APC
If B7 engages CTLA-4 (inhibitory) instead → negative signal; T cell inactivated

Belatacept action:
Recombinant fusion protein of CTLA-4 and IgG1 Fc portion
Binds to B7 molecules (CD80, CD86) on APC
Blocks CD28-B7 interaction
Prevents costimulation signal 2
Result: T-cell anergy (inactivation without first signal); prevents T-cell activation

Advantage over traditional CNI:
Blocks costimulation pathway (earlier step than CNI)
Potentially allows better preservation of T-cell function overall
No nephrotoxicity (vs. CNI)
No hyperglycemia (vs. CNI/corticosteroids)
Potentially preserves renal function

[Doc_4_Immunosuppressive_Drugs:chunk_013] 6.4 Adverse Effects and Concerns
Tokens: 107
--------------------------------------------------------------------------------
Infection risk:
Post-transplant lymphoproliferative disorder (PTLD): Increased risk vs. CNI
~2-4% with belatacept vs. ~1% with CNI
EBV-seropositive recipients at particular risk
Monitor for EBV viremia; consider prophylaxis/preemptive treatment
Management: Reduce belatacept, add CNI, rituximab if PTLD develops
Opportunistic infections: CMV, BK virus, fungal infections
Similar incidence to CNI-based regimens
Appropriate prophylaxis and monitoring recommended

CNS infections:
JC virus-associated progressive multifocal leukoencephalopathy (PML): Rare but serious
Incidence: ~0.1% (uncommon but reported)
Monitor for neurologic symptoms; consider PML PCR if clinical concern

Other adverse effects:
Hypertension: Less than CNI (advantage)
Dyslipidemia: Similar to CNI
Proteinuria: Variable
Infusion reactions: Fever, chills (rare); manageable
Malignancy: Similar to other immunosuppressants; monitor

[Doc_4_Immunosuppressive_Drugs:chunk_014] 7.1 Lymphocyte-Depleting Agents (Induction Therapy)
Tokens: 435
--------------------------------------------------------------------------------
#### Rabbit Anti-Thymocyte Globulin (rATG, Thymoglobulin)

Mechanism:
Polyclonal antiserum derived from immunizing rabbits with human thymocytes
Contains antibodies against multiple T-cell antigens (CD2, CD3, CD4, CD8, CD11a, CD18, CD25, HLA-DR, others)
Causes T-lymphocyte depletion through:
Apoptosis (direct)
Complement-dependent cellular cytotoxicity (CDC)
Antibody-dependent cellular cytotoxicity (ADCC)

Dosing and Administration:
Dose: 1.25-1.5 mg/kg daily × 7-14 days (typical 7-10 days)
IV infusion over 4-6 hours (or longer for first dose)
Premedication: Acetaminophen 650-1000 mg, diphenhydramine 25-50 mg, methylprednisolone 125 mg IV
Timing: Induction therapy (started pre-operatively or day 0-1)

Pharmacology:
Polyclonal; complex PK
Elimination: Combination hepatic/renal; not well characterized
Half-life: Variable; approximately 3-10 days

Efficacy:
Profound T-cell depletion (CD4+ and CD8+ counts drop to near-zero during therapy)
T-cell recovery: Gradual over weeks to months
Prevents acute rejection very effectively: 5-10% incidence (vs. 20-30% without induction)

Adverse Effects:

| System | Effect | Management |
|--------|--------|------------|
| Infusion reactions | Fever, chills, rigors, malaise | Premedicate; antipyretics; slow infusion |
| Hematologic | Thrombocytopenia, neutropenia | Monitor CBC; transfusions if severe |
| Infectious | Increased risk CMV, EBV, BK, fungal | Prophylaxis; monitoring |
| Serum sickness | Fever, rash, arthralgia (days 10-14) | Anti-histamines, NSAIDs, corticosteroids |
| PTLD | EBV-driven B-cell proliferation | Monitor EBV; reduce IS if develops |
| Other | Anaphylaxis (rare), tachycardia, hypertension | Monitor vitals; appropriate support |

Monitoring:
CBC: Monitor for cytopenias
EBV PCR: Baseline, then periodically
CMV antigen/PCR: Baseline, then monitoring
Lymphocyte counts: Pre-dose to assess recovery

#### Alemtuzumab (Campath-1H)

Mechanism:
Humanized monoclonal antibody against CD52
CD52 present on T cells, B cells, monocytes, macrophages, dendritic cells
Causes rapid lymphocyte depletion through CDC and ADCC

Dosing:
Various regimens; common: 0.3 mg/kg IV on day 0 and day 4 (or single 0.3-1 mg/kg dose)
Alternative: 20 mg IV × 1-2 doses
IV infusion; slower than rATG

Advantages over rATG:
Humanized antibody; less immunogenic
More selective (CD52)
Better tolerated; fewer infusion reactions
Can be given in outpatient setting
Faster T-cell recovery (may be advantage or disadvantage depending on context)

Disadvantages:
More profound, prolonged B-cell depletion
May cause more severe lymphopenia
Higher cost

Efficacy and adverse effects: Similar to rATG

#### Basiliximab (Simulect)

Mechanism:
Chimeric mouse-human monoclonal antibody against IL-2 receptor (CD25)
Blocks IL-2 signaling on T cells
Does NOT deplete T cells (blocks costimulation only)

Dosing:
20 mg IV on day 0, day 4 (or day 1, day 5)
Pediatric: 10 mg for <35 kg

Characteristics:
Non-depleting (T cells present but inactive)
Less immunogenic than rATG
Better tolerated
Less effective than depleting agents (higher acute rejection: 10-15% vs. 5-10%)
Preferred in settings where T-cell depletion undesirable (e.g., infection risk)

---

[Doc_4_Immunosuppressive_Drugs:chunk_015] 7.2 B-Cell Directed Therapy: Rituximab
Tokens: 131
--------------------------------------------------------------------------------
Mechanism:
Chimeric mouse-human monoclonal antibody against CD20
CD20 expressed on B-cell precursors through mature B cells (not on plasma cells or hematopoietic stem cells)
Causes B-cell depletion through CDC and ADCC

Dosing:
Desensitization/rejection: 375-500 mg/m² IV × 1-2 doses
Prophylaxis (high-risk): 100-375 mg/m² single dose

Indications:
B-cell depletion induction (controversial; limited evidence as single agent)
Desensitization (combined with IVIG, plasmapheresis)
Antibody-mediated rejection (combined with TPE, IVIG, other agents)
Recurrent PTLD prevention (EBV-positive recipients at high risk)

Efficacy:
Dramatically reduces B-cell populations (90%+ depletion)
DSA reduction when combined with plasmapheresis/IVIG
Concerns: Long-lived bone marrow plasma cells NOT depleted → DSA rebound post-transplant

Adverse effects:
Infusion reactions (fever, chills; milder than rATG)
Infections (especially respiratory; opportunistic)
Severe infections rare but reported
Serum sickness
Hepatitis B reactivation (risk; screen and treat if positive)

---

[Doc_4_Immunosuppressive_Drugs:chunk_016] 8.1 Typical Modern Regimens
Tokens: 118
--------------------------------------------------------------------------------
Kidney transplant (low-risk recipient):
1. Induction: Basiliximab 20 mg day 0, day 4
2. Maintenance: 
Tacrolimus (target 8-12 ng/mL early, 5-8 ng/mL after month 3)
Mycophenolate mofetil 1-1.5 g BID
Prednisolone 5-7.5 mg daily (tapered from 40-60 mg)

Kidney transplant (high-risk: HLA mismatch, sensitized):
1. Induction: rATG 1.25 mg/kg × 7-10 days or alemtuzumab
2. Maintenance:
Tacrolimus (target 10-15 ng/mL initially; higher because of risk)
MPA 1.5 g BID
Prednisolone 7.5-10 mg daily (minimization controversial)
Consider adding mTOR inhibitor or maintaining higher CNI

Steroid-free regimen:
1. Induction: rATG 1.25 mg/kg × 7-10 days
2. Maintenance:
Tacrolimus (target 8-12 ng/mL)
MPA 1.5 g BID
No prednisolone (or tapered off by month 1)
Requires excellent adherence; low immunologic risk

---

[Doc_4_Immunosuppressive_Drugs:chunk_017] 9. KEY CONCEPTS AND SUMMARY
Tokens: 107
--------------------------------------------------------------------------------
1. Multi-drug approach: Modern transplantation uses 3-4 immunosuppressive agents targeting different immune nodes
2. CNI remain cornerstone: Tacrolimus preferred; cyclosporine declining use
3. Antimetabolites essential: MPA superior to AZA; required for adequate suppression
4. Steroids necessary: Despite toxicity; difficult to withdraw
5. mTOR inhibitors: Anti-proliferative benefit; impaired renal recovery limits use
6. Belatacept: Novel mechanism; renal-sparing; PTLD concern
7. Biologic agents: Induction or rejection reversal; infection risk
8. Therapeutic drug monitoring: Essential for CNI; adjust based on levels, clinical response
9. Drug interactions: Extensive; particularly CYP3A4-mediated
10. Adherence critical: Non-adherence → dnDSA, rejection, graft loss

---

Document Version: 1.0 
Evidence Base: AST Clinical Guidelines, Peer-Reviewed Literature (2020-2025)

